Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670904 | 0.87 | CYP11B1 (0.43) | CYP11B1CYP11B2ALDH1A1SIRT2ENPP2 | |
| SCHEMBL5682164 | 0.87 | CYP11B1 (0.43) | CYP11B1CYP11B2SIRT2ENPP2KMT2A | |
| SCHEMBL9488291 | 0.85 | CYP11B1 (0.37) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL9488294 | 0.85 | CYP11B1 (0.37) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL9488286 | 0.85 | CYP11B1 (0.37) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL28422181 | 0.84 | ADA (0.47) | CYP11B1CYP11B2SIRT2ENPP2MAPT | |
| SCHEMBL693097 | 0.84 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2ENPP2MAPT | |
| SCHEMBL1414845 | 0.83 | SIRT2 (0.41) | CYP11B1CYP11B2ALDH1A1SIRT2ENPP2 | |
| SCHEMBL1829222 | 0.83 | SIRT2 (0.47) | ALDH1A1SIRT2KDM4EMAPTKMT2A | |
| SCHEMBL28415779 | 0.83 | BRD4 (0.40) | CYP11B1CYP11B2SIRT2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| CN-119979476-A | Hybridoma cell strain secreting clotrimazole monoclonal antibody and application thereof | 江南大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024260319-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-12-26 | — | — | WO | disclosed |
| WO-2024240240-A1 | IMIDAZOLE DERIVATIVES, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-112979552-B | Preparation method of high-purity dexmedetomidine hydrochloride | 广安凯特制药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112979552-A | Preparation method of high-purity dexmedetomidine hydrochloride | 广安凯特制药有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-2888259-B1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | NOVARTIS AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-5658938-A | HYPOTENSIVE AGENT, ANTIISCHMIC AGENTS | U C B S.A. (BE) | 1997-08-19 | — | — | US | disclosed |
| EP-0717037-A1 | Substituted 1H-imidazoles having alpha 2-agonistic and alpha 1-antagonistic activity | U C B, S.A. (BE) | 1996-06-19 | — | — | EP | disclosed |
| EP-0269599-B1 | Substituted 1H-imidazoles | UCB SA (BE) | 1993-12-15 | — | — | EP | disclosed |
| US-5243043-A | Cephalosporin antibiotics and bactericides | ROUSSEL UCLAF (FR) | 1993-09-07 | — | — | US | disclosed |
| EP-0338939-B1 | HISTAMINE DERIVATIVE, PROCESS FOR HIS PREPARATION AND HIS THERAPEUTIC APPLICATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-01-27 | — | — | EP | disclosed |
| US-5034539-A | Histamine derivative, process for preparing it and its therapeutic use | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1991-07-23 | — | — | US | disclosed |
| US-4992431-A | Bactericides or antibiotics | ROUSSELUCLAF (FR) | 1991-02-12 | — | — | US | disclosed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | disclosed |
| US-4814343-A | ANTIISCHEMIC | U C B, S.A. (BE) | 1989-03-21 | — | — | US | disclosed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | ADRB1, ADRB2, BRD4 | CYP11B1 25/4885CYP11B2 13/4885ALDH1A1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.